Background： Atopic dermatitis （AD） is an inflammatory skin disease characterized by chronic recurrent dermatitis with profound itching. Most patients have personal and/or family history of atopic diseases. Several ...Background： Atopic dermatitis （AD） is an inflammatory skin disease characterized by chronic recurrent dermatitis with profound itching. Most patients have personal and/or family history of atopic diseases. Several criteria have been proposed for the diagnosis of AD. Although the clinical features of childhood AD have been widely studied, there has been less large-scale study on adult/adolescent AD. The aim of this study was to investigate the clinical features of adult/adolescent patients with chronic symmetrical eczemaJAD and to propose Chinese diagnostic criteria for adult/adolescent AD. Methods： A hospital-based study was performed. Forty-two dermatological centers participated in this study. Adult and adolescent patients （12 years and over） with chronic symmetrical eczema or AD were included in this study. Questionnaires were completed by both patients and-investigators. The valid questionnaires were analyzed using EpiData 3.1 and SPSS 17.0 software. Results： A total of 2662 valid questionnaires were collected （1369 male and 1293 female）. Of all 2662 patients, 2062 （77.5%） patients had the disease after 12 years old, while only 600 （22.5%） patients had the disease before 12 years old, suggesting late-onset eczema/AD is common. Two thousand one hundred and thirty-nine （80.4%） patients had the disease for more than 6 months. One thousand one hundred and forty-four （43.0%） patients had a personal and/or family history of atopic diseases. One thousand five hundred and forty-eight （58.2%） patients had an elevated total serum IgE and/or eosinophilia and/or positive allergen-specific IgE. Based on these clinical and laboratory features, we proposed Chinese criteria for adult/adolescent AD. Of all 2662 patients, 60.3% were satisfied with our criteria, while only 48.2% satisfied with Hanifin Rajka criteria and 32.7% satisfied with Williams criteria, suggesting a good sensitivity of our criteria in adult/adolescent AD patients. Conclusion： Late-onset of eczema or AD is common. Th展开更多
特应性皮炎是一种复发性的以严重瘙痒为主要临床表现的慢性过敏性皮肤病。全球特应性皮炎的患病率不断上升,然而其发病机制尚不明确。"Outside to inside"是近几年对于特应性皮炎发病机制阐述较为完善的假说,该假说提示特应...特应性皮炎是一种复发性的以严重瘙痒为主要临床表现的慢性过敏性皮肤病。全球特应性皮炎的患病率不断上升,然而其发病机制尚不明确。"Outside to inside"是近几年对于特应性皮炎发病机制阐述较为完善的假说,该假说提示特应性皮炎的发病可能是由皮肤向免疫、由外向内渐进性的过程。展开更多
目的在临床实际应用中,对2020年6月在中国被批准用于治疗中重度特应性皮炎(atopic dermatitis,AD)患者的度普利尤单抗的有效性和安全性进行评估。方法对20例经局部和/或全身用药控制不佳的中重度AD患者采用度普利尤单抗皮下注射治疗满1...目的在临床实际应用中,对2020年6月在中国被批准用于治疗中重度特应性皮炎(atopic dermatitis,AD)患者的度普利尤单抗的有效性和安全性进行评估。方法对20例经局部和/或全身用药控制不佳的中重度AD患者采用度普利尤单抗皮下注射治疗满16周。评估湿疹面积和严重程度指数(eczema area and severity index,EASI)、瘙痒数值评分量表(numerical,NRS)评分变化,及其与总IgE和嗜酸性粒细胞水平的相关性,以及该药的安全性。结果基线时(第0周)和治疗后第4、8和16周时的平均EASI评分(±标准差)分别为(28.4±9.9),(12.8±7.3),(7.8±6.6)和(4.3±4.4);基线期和治疗后第4、8和16周时的瘙痒平均NRS评分(±标准差)分别为(8.1±1.2),(4.7±1.5),(3.6±1.4)和(2.3±1.2)。本研究未发现总IgE和嗜酸性粒细胞水平与疗效变化的相关性。20例患者治疗过程及随访中未出现显著不良反应。结论度普利尤单抗能显著改善中重度AD患者的EASI评分和瘙痒NRS评分,且具有良好的安全性。展开更多
文摘Background： Atopic dermatitis （AD） is an inflammatory skin disease characterized by chronic recurrent dermatitis with profound itching. Most patients have personal and/or family history of atopic diseases. Several criteria have been proposed for the diagnosis of AD. Although the clinical features of childhood AD have been widely studied, there has been less large-scale study on adult/adolescent AD. The aim of this study was to investigate the clinical features of adult/adolescent patients with chronic symmetrical eczemaJAD and to propose Chinese diagnostic criteria for adult/adolescent AD. Methods： A hospital-based study was performed. Forty-two dermatological centers participated in this study. Adult and adolescent patients （12 years and over） with chronic symmetrical eczema or AD were included in this study. Questionnaires were completed by both patients and-investigators. The valid questionnaires were analyzed using EpiData 3.1 and SPSS 17.0 software. Results： A total of 2662 valid questionnaires were collected （1369 male and 1293 female）. Of all 2662 patients, 2062 （77.5%） patients had the disease after 12 years old, while only 600 （22.5%） patients had the disease before 12 years old, suggesting late-onset eczema/AD is common. Two thousand one hundred and thirty-nine （80.4%） patients had the disease for more than 6 months. One thousand one hundred and forty-four （43.0%） patients had a personal and/or family history of atopic diseases. One thousand five hundred and forty-eight （58.2%） patients had an elevated total serum IgE and/or eosinophilia and/or positive allergen-specific IgE. Based on these clinical and laboratory features, we proposed Chinese criteria for adult/adolescent AD. Of all 2662 patients, 60.3% were satisfied with our criteria, while only 48.2% satisfied with Hanifin Rajka criteria and 32.7% satisfied with Williams criteria, suggesting a good sensitivity of our criteria in adult/adolescent AD patients. Conclusion： Late-onset of eczema or AD is common. Th
文摘目的在临床实际应用中,对2020年6月在中国被批准用于治疗中重度特应性皮炎(atopic dermatitis,AD)患者的度普利尤单抗的有效性和安全性进行评估。方法对20例经局部和/或全身用药控制不佳的中重度AD患者采用度普利尤单抗皮下注射治疗满16周。评估湿疹面积和严重程度指数(eczema area and severity index,EASI)、瘙痒数值评分量表(numerical,NRS)评分变化,及其与总IgE和嗜酸性粒细胞水平的相关性,以及该药的安全性。结果基线时(第0周)和治疗后第4、8和16周时的平均EASI评分(±标准差)分别为(28.4±9.9),(12.8±7.3),(7.8±6.6)和(4.3±4.4);基线期和治疗后第4、8和16周时的瘙痒平均NRS评分(±标准差)分别为(8.1±1.2),(4.7±1.5),(3.6±1.4)和(2.3±1.2)。本研究未发现总IgE和嗜酸性粒细胞水平与疗效变化的相关性。20例患者治疗过程及随访中未出现显著不良反应。结论度普利尤单抗能显著改善中重度AD患者的EASI评分和瘙痒NRS评分,且具有良好的安全性。
